AntiTumor mechanism of recombinant murine interleukin-12 vaccine

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 3, 2010, Pages 263-268

  Yin, Xiaoling ^a,b   Yan, Xuexian ^c   Yang, Qinan ^d   Cao, Hui ^e   Liang, Houjie ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Chongqing Steel and Iron Group Co   (China)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Department of Internal Medicine   (China)

^e CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

antitumor mechanism; gene therapy; Lewis lung carcinoma; murine interleukin 12; tumor vaccine

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; LEWIS LUNG CARCINOMA CELL VACCINE; PHOSPHATE BUFFERED SALINE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER TISSUE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG CARCINOMA; MOLECULAR CLONING; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCREENING; TUMOR VOLUME; VACCINATION;

ANIMALS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CHEMOKINE CXCL10; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-12; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MICROVESSELS; RECOMBINANT PROTEINS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 77954950430     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0771     Document Type: Article

References (36)

1. Nagarajan S, Selvaraj P. Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro. A potential approach for local delivery of cytokines during vaccination. Vaccine 2006;24:2264.
2. Salem ML, Kadima AN, Zhou Y, et al. Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J Immunol 2004;172:5159.
3. Verma V, Sharma V, Shrivastava SK, et al. IL-12 and IL-2 potentiate the tumor-specific activity of peripheral blood cells from cervical cancer patients in vitro. J Exp Clin Cancer Res 2000;19:367.
4. Ahn WS, Bae SM, Kim TY, et al. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum Gene Ther 2003;14:1389.
5. Keke F, Hongyang Z, Hui Q, et al. A combination of flk1- based DNA vaccine and an immunomodulatory gene (IL-12) in the treatment of murine cancer. Cancer Biother Radio- pharm 2004;19:649.
6. Suzuki S, Umezu Y, Saijo Y, et al. Exogenous recombinant human IL-12 augments MHC class I antigen expression on human cancer cells in vitro. Tohoku J Exp Med 1998; 185:223.
7. Oshikawa K, Ishii Y, Hamamoto T, et al. Particle-mediated gene transfer of murine interleukin-12 cDNA suppresses the growth of Lewis lung carcinoma. In Vivo 1999;13:397.
8. Pressley JS, Elgert KD. Post-chemotherapeutic administration of interleukin-12 retards tumor growth and enhances immune cell function: Combination therapy using paclitaxel and IL-12. Cancer Invest 2006;24:351.
9. Tamura T, Nishi T, Goto T, et al. Combination of IL-12 and IL-18 of electro-gene therapy synergistically inhibits tumor growth. Anticancer Res 2003;23:1173.
10. Cebon J, Jager E, Shackleton MJ, et al. Two phase I studies of low dose recombinant human IL-12 with melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun 2003;3:7.
11. Duvic M, Sherman ML, Wood GS, et al. A phase II open- label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 2006;55:807.
12. Gollob JA, Mier JW, Veenstra K, et al. Phase I trial of twice- weekly intravenous interleukin 12 in patients with meta- static renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000;6:1678.
13. Gollob JA, Veenstra KG, Parker RA, et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 2003;21:2564.
14. Motzer RJ, Rakhit A, Schwartz LH, et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998;4:1183.
15. Motzer RJ, Rakhit A, Thompson JA, et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 vs. interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2001;21:257.
16. Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin- 12 for advanced digestive tumors. J Clin Oncol 2004;22: 1389.
17. Imagawa Y, Satake K, Kato Y, et al. Antitumor and anti- angiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model. Auris Nasus Larynx 2004;31:239.
18. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogen esis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;87:3877.
19. Takeuchi E, Yanagawa H, Suzuki Y, et al. IL-12-induced production of IL-10 and interferon-gamma by mononuclear cells in lung cancer-associated malignant pleural effusions. Lung Cancer 2002;35:171.
20. Yin X-L, Sun S-L, Li S-L. The construction and expression of murine interleukin-12 eukaryotic expression plasmid. Chinese journal of cancer prevention and treatment 2006; 13:165.
21. Yin X-L, Duan H, Pen Z-P. The empirical study on murine Lewis lung carcinoma treated by recombinate murine in- terleukin-12. Cancer 2006;25:1087.
22. NCCLS. Clinical applications of flow cytometry: Quality assurance and immunophenotyping of peripheral blood lymphocytes. NCCLS Document H42-T 1992;12:1.
23. Liu Y, Ehtesham M, Samoto K, et al. In situ adenoviral interleukin 12 gene transfer confers potent and long- lasting cytotoxic immunity in glioma. Cancer Gene Ther 2002;9:9.
24. Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci 2000; 97:2208.
25. Yamanaka R, Zullo SA, Ramsey J, et al. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing semliki forest virus-mediated interleukin-12. J Neurosurg 2002;97:611.
26. Ren H, Boulikas T, Lundstrom K, et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent semliki forest virus vector carrying the human interleukin-12 gene: A phase I/II clinical protocol. J Neurooncol 2003;64:147.
27. Roy EJ, Gawlick U, Orr BA, et al. IL-12 treatment of en- dogenously arising murine brain tumors. J Immunol 2000; 165:7293.
28. Jean WC, Spellman SR, Wallenfriedman MA, et al. Interleukin-12-based immunotherapy against rat 9L glioma. Neurosurgery 1998;42:850.
29. Ha SJ, Lee SB, Kim CM, et al. Rapid recruitment of macro- phages in interleukin-12-mediated tumor regression. Immunology 1998;95:152.
30. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. Exp Med 1993;178:1223.
31. Knutson KL, Disis ML. IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol 2004;135:322.
32. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155.
33. Satoh Y, Esche C, Gambotto A, et al. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol 1998;2:337.
34. Desaknai S, Lumniczky K, Hidvegi EJ, et al. Brain tumor treatment with IL-2 and IL-12 producing autologous cancer cell vaccines. Adv Exp Med Biol 2001;495:369.
35. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of gli- oma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004; 27:452.
36. Fewell JG, Matar M, Slobodkin G, et al. Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer. J Controlled Release 2005;109:288.